European Journal of Vascular & Endovascular Surgery
Volume 36, Issue 2 , Pages 132-137 , August 2008

Increased Platelet-monocyte Aggregation in Male Claudicants with the PlA1/A2 Polymorphism of Gp IIb/IIIa

  • J. McCaslin

      Affiliations

    • Queen Elizabeth Hospital, Gateshead, UK
    • ,
  • H. Ashour

      Affiliations

    • Queen Elizabeth Hospital, Gateshead, UK
    • ,
  • V. Bhattacharya

      Affiliations

    • Queen Elizabeth Hospital, Gateshead, UK
    • ,
  • M. Cleanthis

      Affiliations

    • Northern Vascular Unit, Freeman Hospital, Newcastle-upon-Tyne, UK
    • ,
  • A. Daly

      Affiliations

    • Newcastle University, Newcastle, UK
    • ,
  • G. Stansby

      Affiliations

    • Northern Vascular Unit, Freeman Hospital, Newcastle-upon-Tyne, UK
    • Corresponding Author InformationCorresponding author. Prof G. Stansby, Northern Vascular Unit, Freeman Hospital, Newcastle-upon-Tyne NE7 7DN, UK. Tel.: +191 2231125; fax: +191 2231489.

Received 31 October 2007 ,Accepted 15 February 2008.

References 

  1. Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldschmidt-Clermont PJ. PlA2 polymorphism and efficacy of aspirin. Lancet. 1998;351(9111):1253
  2. Szczeklik A, Undas A, Sanak M, Frolow M, Wegrzyn W. Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol. 2000;110(4):965–967
  3. Undas A, Sanak M, Musial J, Szczeklik A. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. [comment] Lancet. 1999;353(9157):982–983
  4. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. [see comment] N Engl J Med. 1996;334(17):1090–1094
  5. Feng D, Lindpaintner K, Larson MG, O'Donnell CJ, Lipinska I, Sutherland PA, et al. Platelet glycoprotein IIIa Pl(a) polymorphism, fibrinogen, and platelet aggregability: the Framingham Heart Study. Circulation. 2001;104(2):140–144
  6. Faraday N, Martinez EA, Scharpf RB, Kasch-Semenza L, Dorman T, Pronovost PJ, et al. Platelet gene polymorphisms and cardiac risk assessment in vascular surgical patients. Anesthesiology. 2004;101(6):1291–1297
  7. Meiklejohn DJ, Urbaniak SJ, Greaves M. Platelet glycoprotein IIIa polymorphism HPA 1b (PlA2): no association with platelet fibrinogen binding. Br J Haematol. 1999;105(3):664–666
  8. Smith FB, Connor JM, Lee AJ, Cooke A, Lowe GDO, Rumley A, et al. Relationship of the platelet glycoprotein PlA and fibrinogen T/G+1689 polymorphisms with peripheral arterial disease and ischaemic heart disease. Thromb Res. 2003;112(4):209–216
  9. Li N, Goodall AH, Hjemdahl P. A sensitive flow cytometric assay for circulating platelet-leucocyte aggregates. Br J Haematol. 1997;99(4):808–816
  10. Feng D, Lindpaintner K, Larson MG, Rao VS, O'Donnell CJ, Lipinska I, et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 1999;19(4):1142–1147
  11. Goodall AH, Curzen N, Panesar M, Hurd C, Knight CJ, Ouwehand WH, et al. Increased binding of fibrinogen to glycoprotein IIIa-proline33 (HPA-1b, PlA2, Zwb) positive platelets in patients with cardiovascular disease. [see comment] Eur Heart J. 1999;20(10):742–747
  12. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. [see comment] Circulation. 2000;101(9):1013–1018
  13. Lasne D, Krenn M, Pingault V, Arnaud E, Fiessinger JN, Aiach M, et al. Interdonor variability of platelet response to thrombin receptor activation: influence of PlA2 polymorphism. Br J Haematol. 1997;99(4):801–807
  14. Bennett JS, Catella-Lawson F, Rut AR, Vilaire G, Qi W, Kapoor SC, et al. Effect of the Pl(A2) alloantigen on the function of beta(3)-integrins in platelets. Blood. 2001;97(10):3093–3099
  15. Robless PA, Tegos TJ, Okonko D, Mansfield AO, Nicolaides AN, Mikhailidis DP, et al. Platelet activation during carotid endarterectomy and the antiplatelet effect of Dextran 40. Platelets. 2002;13(4):231–239
  16. Robless PA, Okonko D, Lintott P, Mansfield AO, Mikhailidis DP, Stansby GP. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2003;25(1):16–22
  17. Schmitz G, Rothe G, Ruf A, Barlage S, Tschope D, Clemetson KJ, et al. European working group on clinical cell analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost. 1998;79(5):885–896
  18. Sorel N, Brabant S, Christiaens L, Brizard A, Mauco G, Macchi L. A rapid and specific whole blood HPA-1 phenotyping by flow cytometry using two commercialized monoclonal antibodies directed against GP IIIa and GP IIb-IIIa complexes. Br J Haematol. 2004;124(2):221–223
  19. Mikkelsson J, Perola M, Laippala P, Penttila A, Karhunen PJ. Glycoprotein IIIa Pl(A1/A2) polymorphism and sudden cardiac death. J Am Coll Cardiol. 2000;36(4):1317–1323
  20. Unkelbach K, Kalb R, Santoso S, Kroll H, Mueller-Eckhardt C, Kiefel V. Genomic RFLP typing of human platelet alloantigens Zw(PlA), Ko, Bak and Br (HPA-1, 2, 3, 5). Br J Haematol. 1995;89(1):169–176
  21. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. [see comment] J Am Coll Cardiol. 2003;41(6):961–965
  22. Jefferson BK, Foster JH, McCarthy JJ, Ginsburg G, Parker A, Kottke-Marchant K, et al. Aspirin resistance and a single gene. Am J Cardiol. 2005;95(6):805–808
  23. Lepantalo A, Mikkelson J, Resendiz JC, Viiri L, Backman JT, Kankuri E, et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost. 2006;95:253–259
  24. Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events?. J Am Coll Cardiol. 2003;41(6):966–968
  25. Boudoulas KD, Cooke GE, Roos CM, Bray PF, Goldschmidt-Clermont PJ. The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. Arch Pathol Lab Med. 2001;125(1):112–115
  26. Boudoulas KD, Montague CR, Goldschmidt-Clermont PJ, Cooke GE. Estradiol increases platelet aggregation in Pl(A1/A1) individuals. Am Heart J. 2006;152(1):136–139
  27. Rinder CS, Gaal D, Student LA, Smith BR. Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1994;107(1):280–288
  28. Serrano CV, Ramires JA, Venturinelli M, Arie S, D'Amico E, Zweier JL, et al. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol. 1997;29(6):1276–1283
  29. Serrano CV, Rocha Giraldez R, de Lara Fernandes J, Nicolau JC, Zweier JL, Ramires JAF. Platelet and leukocyte adhesion and activation in unstable angina and post-PTCA. Int J Cardiol. 2005;99(3):423–428
  30. Mickelson JK, Lakkis NM, Villarreal-Levy G, Hughes BJ, Smith CW. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease?. J Am Coll Cardiol. 1996;28(2):345–353
  31. Htun P, Fateh-Moghadam S, Tomandl B, Handschu R, Klinger K, Stellos K, et al. Course of platelet activation and platelet-leukocyte interaction in cerebrovascular ischemia. Stroke. 2006;37(9):2283–2287
  32. Gawaz M, Reininger A, Neumann FJ. Platelet function and platelet-leukocyte adhesion in symptomatic coronary heart disease. Effects of intravenous magnesium. Thromb Res. 1996;83(5):341–349
  33. May AE, Neumann FJ, Gawaz M, Ott I, Walter H, Schomig A. Reduction of monocyte-platelet interaction and monocyte activation in patients receiving antiplatelet therapy after coronary stent implantation. Eur Heart J. 1997;18(12):1913–1920
  34. Zimmerman GA, Elstad MR, Lorant DE, McLntyre TM, Prescott SM, Topham MK, et al. Platelet-activating factor (PAF): signalling and adhesion in cell-cell interactions. Adv Exp Med Biol. 1996;416:297–304
  35. Weyrich AS, Elstad MR, McEver RP, McIntyre TM, Moore KL, Morrissey JH, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest. 1996;97(6):1525–1534
  36. Furie B, Furie BC. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Thromb Haemost. 1995;74(1):224–227
  37. Spangenberg P, Redlich H, Bergmann I, Losche W, Gotzrath M, Kehrel B. The platelet glycoprotein IIb/IIIa complex is involved in the adhesion of activated platelets to leukocytes. Thromb Haemost. 1993;70(3):514–521
  38. Sanderson HM, Fox SC, Robbins RA, Losche W, Spangenberg P, Heptinstall S. Role of GPIIb-IIIa in platelet-monocyte and platelet-neutrophil conjugate formation in whole blood. Platelets. 1998;9(3–4):245–250
  39. Neumann FJ, Zohlnhofer D, Fakhoury L, Ott I, Gawaz M, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol. 1999;34(5):1420–1426
  40. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001;104(13):1533–1537
  41. Rosin C, Brunner M, Lehr S, Quehenberger P, Panzer S. The formation of platelet-leukocyte aggregates varies during the menstrual cycle. Platelets. 2006;17(1):61–66
  42. Aldrighi JM, Oliveira RLS, D'Amico E, Rocha TRF, Gebara OE, Rosano GMC, et al. Platelet activation status decreases after menopause. Gynecol Endocrinol. 2005;20(5):249–257
  43. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308(6921):81–106
  44. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – II: maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ. 1994;308(6922):159–168
  45. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ. 1994;308(6923):235–246
  46. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. [see comment] Lancet. 1988;2(8607):349–360
  47. CAPRIE investigators . Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE Trial). Am J Cardiol. 2002;90(7):760–762
  48. CURE Study Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502

PII: S1078-5884(08)00155-X

doi: 10.1016/j.ejvs.2008.02.016

European Journal of Vascular & Endovascular Surgery
Volume 36, Issue 2 , Pages 132-137 , August 2008

Article Tools

* Image Usage & Resolution